The paucity of research on HDAC6 inhibition in PD models and the conflicting literature on HDAC6 regulation of tau pathology led us to assess HDAC6 inhibition in a wild-type (WT) mouse model with concurrent tau and α-synuclein pathology. The gene discussed is MAPT; the disease is Parkinson disease.